DRD1 and breast carcinoma: Selective D1 receptor agonist fenoldopam and l-SPD (l-stepholidine), D1R agonist and D2R antagonist, display inhibitory potential on metastatic breast cancer cell lines MDA-MB-231 and 4T1 [53,75].